These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 25167216)

  • 21. Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα.
    Castro-Villegas C; Pérez-Sánchez C; Escudero A; Filipescu I; Verdu M; Ruiz-Limón P; Aguirre MA; Jiménez-Gomez Y; Font P; Rodriguez-Ariza A; Peinado JR; Collantes-Estévez E; González-Conejero R; Martinez C; Barbarroja N; López-Pedrera C
    Arthritis Res Ther; 2015 Mar; 17(1):49. PubMed ID: 25860297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synovial Inflammatory Pathways Characterize Anti-TNF-Responsive Rheumatoid Arthritis Patients.
    Wang J; Conlon D; Rivellese F; Nerviani A; Lewis MJ; Housley W; Levesque MC; Cao X; Cuff C; Long A; Pitzalis C; Ruzek MC
    Arthritis Rheumatol; 2022 Dec; 74(12):1916-1927. PubMed ID: 35854416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting best treatment in rheumatoid arthritis.
    Lewis MJ
    Semin Arthritis Rheum; 2024 Feb; 64S():152329. PubMed ID: 38008706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis.
    Zamora-Atenza C; Diaz-Torne C; Geli C; Diaz-Lopez C; Ortiz MA; Moya P; Castellví I; Nieto JC; Cantó E; Casademont J; Juarez C; Llobet JM; Vidal S
    Arthritis Res Ther; 2014 Jul; 16(4):R153. PubMed ID: 25037855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium.
    Wijbrandts CA; Dijkgraaf MG; Kraan MC; Vinkenoog M; Smeets TJ; Dinant H; Vos K; Lems WF; Wolbink GJ; Sijpkens D; Dijkmans BA; Tak PP
    Ann Rheum Dis; 2008 Aug; 67(8):1139-44. PubMed ID: 18055470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
    Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
    Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study.
    Taylor PC; Schiff MH; Wang Q; Jiang Y; Zhuang Y; Kurrasch R; Daga S; Rao R; Tak PP; Hsu B
    Ann Rheum Dis; 2018 May; 77(5):658-666. PubMed ID: 29483080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial.
    Rivellese F; Surace AEA; Goldmann K; Sciacca E; Çubuk C; Giorli G; John CR; Nerviani A; Fossati-Jimack L; Thorborn G; Ahmed M; Prediletto E; Church SE; Hudson BM; Warren SE; McKeigue PM; Humby F; Bombardieri M; Barnes MR; Lewis MJ; Pitzalis C;
    Nat Med; 2022 Jun; 28(6):1256-1268. PubMed ID: 35589854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Common Transcriptomic Effects of Abatacept and Other DMARDs on Rheumatoid Arthritis Synovial Tissue.
    Triaille C; Durez P; Sokolova T; Tilman G; Méric de Bellefon L; Galant C; Coulie P; Lauwerys BR; Limaye N
    Front Immunol; 2021; 12():724895. PubMed ID: 34526997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT study.
    Haraoui B; Cividino A; Stewart J; Guérette B; Keystone EC
    BMC Musculoskelet Disord; 2011 Nov; 12():261. PubMed ID: 22093579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature.
    Scrivo R; Conti F; Spinelli FR; Truglia S; Magrini L; Di Franco M; Ceccarelli F; Valesini G
    Reumatismo; 2009; 61(2):107-17. PubMed ID: 19633797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.
    Burmester GR; Mariette X; Montecucco C; Monteagudo-Sáez I; Malaise M; Tzioufas AG; Bijlsma JW; Unnebrink K; Kary S; Kupper H
    Ann Rheum Dis; 2007 Jun; 66(6):732-9. PubMed ID: 17329305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study.
    Monnet E; Choy EH; McInnes I; Kobakhidze T; de Graaf K; Jacqmin P; Lapeyre G; de Min C
    Ann Rheum Dis; 2020 Mar; 79(3):316-323. PubMed ID: 31892533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of gene expression signatures related to underlying disease and treatment in rheumatoid arthritis patients.
    Serikawa KA; Jacobsen S; Lundsgaard D; Fox BA; Hummelshoj L; Poulsen LK; Fleckner J; Frederiksen KS
    Mod Rheumatol; 2013 Jul; 23(4):729-40. PubMed ID: 22872428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response.
    Gibbons LJ; Hyrich KL
    BioDrugs; 2009; 23(2):111-24. PubMed ID: 19489652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The predictive value of serum soluble ICAM-1 and CXCL13 in the therapeutic response to TNF inhibitor in rheumatoid arthritis patients who are refractory to csDMARDs.
    Zhao J; Ye X; Zhang Z
    Clin Rheumatol; 2020 Sep; 39(9):2573-2581. PubMed ID: 32206975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.